Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)

Stock Information for Outlook Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Outlook Therapeutics Inc.

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg) Accepted by FDA
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
Outlook Therapeutics Announces Proposed Public Offering
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.